SARS‐CoV‐2‐specific humoral and cell‐mediated immune responses after immunization with inactivated COVID‐19 vaccine in kidney transplant recipients (CVIM 1 study)

Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection

(2021) Jianmin Zuo et al.   NATURE IMMUNOLOGY

Outcomes of Coronavirus Infectious Disease -19 (COVID-19) in Solid Organ Transplant Recipients

(2021) Yousaf B Hadi et al.   TRANSPLANTATION

An Open-Label Randomized Controlled Parallel-Group Pilot Study Comparing the Immunogenicity of a Standard-, Double- And Booster-Dose Regimens of the 2014 Seasonal Trivalent Inactivated Influenza Vaccine In Kidney Transplant Recipients.

(2021) Fatuma Catherine Atieno Odongo et al.   TRANSPLANTATION

Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients

(2021) Brian J. Boyarsky et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

(2021) Brian J. Boyarsky et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

(2021) David S. Khoury et al.   NATURE MEDICINE

Cellular and humoral response after MRNA‐1273 SARS‐CoV‐2 vaccine in kidney transplant recipients

(2021) David Cucchiari et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Safety and Immunogenicity of Anti–SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants

(2021) Olivier Marion et al.   ANNALS OF INTERNAL MEDICINE

Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2

(2021) Dami A. Collier et al.   NATURE

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

(2021) Alejandro Jara et al.   NEW ENGLAND JOURNAL OF MEDICINE

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

(2021) Nassim Kamar et al.   NEW ENGLAND JOURNAL OF MEDICINE

COVID-19 in Kidney Transplant Recipients Vaccinated With Oxford–AstraZeneca COVID-19 Vaccine (Covishield): A Single-center Experience From India

(2021) Hari Shankar Meshram et al.   TRANSPLANTATION

COVID-19 in Immunocompromised Hosts: What We Know So Far

(2020) Monica Fung et al.   CLINICAL INFECTIOUS DISEASES

Clinical evaluation of serological IgG antibody response on the Abbott Architect for established SARS-CoV-2 infection

(2020) K.L. Chew et al.   CLINICAL MICROBIOLOGY AND INFECTION

A case of successful treatment of severe COVID‐19 pneumonia with favipiravir and tocilizumab in post–kidney transplant recipient

(2020) Theerachai Thammathiwat et al.   Transplant Infectious Disease

A family cluster of diagnosed coronavirus disease 2019 (COVID‐19) kidney transplant recipient in Thailand

(2020) Parichart Sakulkonkij et al.   Immunity Inflammation and Disease

Clinical characteristics and risk factors for coronavirus disease 2019 (COVID-19) among patients under investigation in Thailand

(2020) Jackrapong Bruminhent et al.   PLoS One

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

(2020) Yanjun Zhang et al.   LANCET INFECTIOUS DISEASES

Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults

(2014) Carlos A. DiazGranados et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of the Immunogenicity of a Monovalent Influenza A/H1N1 2009 Vaccine Between Healthy Individuals, Patients With Chronic Renal Failure, and Immunocompromised Populations

(2014) S.P. Watcharananan et al.   TRANSPLANTATION PROCEEDINGS